Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | DTYMK | P23919 | 2/20 | 0.49 |
| ▸ | POLG | P54098 | 2/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.48 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152753 | 1.00 | ADRB1 (0.64) | ADRB1DNMT1POLBP2RY2P2RY4 | |
| SCHEMBL1152822 | 0.90 | ADRB1 (0.71) | ADRB1DNMT1POLBNT5EENPP1 | |
| SCHEMBL26031224 | 0.86 | POLB (0.56) | ADRB1DNMT1POLBP2RY2P2RY4 | |
| SCHEMBL12932288 | 0.86 | POLB (0.56) | ADRB1DNMT1POLBP2RY2P2RY4 | |
| SCHEMBL15810820 | 0.86 | POLB (0.56) | ADRB1DNMT1POLBP2RY2P2RY4 | |
| Deoxycytidine Triphosphate SCHEMBL703664 | 0.84 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL42135 | 0.84 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL29725285 | 0.84 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL18785037 | 0.84 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL1615548 | 0.84 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2017-03-16 | — | — | US | disclosed |
| US-9498489-B2 | Antimetabolite agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-20100267657-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | CASE WESTERN RESERVE UNIVERSITY | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267657-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | DNASE1, DNASE1L3, UNG | ADRB1 4555/4885DNMT1 188/4885POLB 24/4885 |
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | DNASE1, DNASE1L3, UNG | ADRB1 4555/4885DNMT1 188/4885POLB 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.